A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously

被引:2
|
作者
Mezei, Zoltan A. [1 ]
Tornai, David [1 ]
Foldesi, Roza [1 ]
Madar, Laszlo [1 ]
Sumegi, Andrea [2 ]
Papp, Maria [3 ]
Antal-Szalmas, Peter [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Lab Med, Nagyerdei Str 98, H-4032 Debrecen, Hungary
[2] Hungarian Acad Sci, HAS UD Vasc Biol & Myocardial Pathophysiol Res Gr, Nagyerdei Str 98, H-4032 Debrecen, Hungary
[3] Univ Debrecen, Fac Med, Dept Internal Med, Div Gastroenterol, Nagyerdei Str 98, H-4032 Debrecen, Hungary
关键词
Fms-like tyrosine kinase 3 (FLT3); Internal tandem duplication (ITD); Deep next generation sequencing (NGS); Analytical validation; INTERNAL TANDEM DUPLICATION; MINIMAL RESIDUAL DISEASE; ACUTE MYELOID-LEUKEMIA; ASSAY; PINDEL;
D O I
10.1016/j.jbiotec.2019.06.305
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Internal tandem duplication (ITD) in the fms-like tyrosine kinase 3 (FLT3) gene is one of the most frequent genetic alteration in acute myeloid leukemia (AML), and it is associated with worse clinical outcome. Not only the presence but also the size, localization and the rate of this variant or the presence of multiple ITDs has prognostic information. The traditional PCR based diagnostic methods cannot provide information about all of these parameters in one assay, however the application of next generation sequencing (NGS) technique can be a reliable solution for this diagnostic problem. In order to evaluate the analytical properties of an NGS-based FLT3-ITD detection assay a quality control sample was prepared from DNA of AML patients containing 19 different FLT3-ITD variants identified by NGS. The higher the total read count was in a certain sample of the NGS run, the more ITD variant types could be detected. The maximal sensitivity of FLT3-ITD detection by NGS technique was as low as 0.007% FLT3-ITD/total allele rate, however, below 0.1% rate, the reproducibility of the quantitation was poor (CV > 25%). DNA pools with several FLT3-ITDs can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation testing several different ITD sequences and rates, simultaneously.
引用
收藏
页码:25 / 29
页数:5
相关论文
共 32 条
  • [21] FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
    Soare, Dan-Sebastian
    Radu, Eugen
    Dumitru, Ion
    Popov, Viola Maria
    Bumbea, Horia
    Vladareanu, Ana Maria
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (13) : 7675 - 7679
  • [22] Reverse Electrochemical Sensing of FLT3-ITD Mutations in Acute Myeloid Leukemia Using Gold Sputtered ZnO-Nanorod Configured DNA Biosensors
    Thevendran, Ramesh
    Foo, Kai Loong
    Hussin, Mohd Hazwan
    Moses, Emmanuel Jairaj
    Citartan, Marimuthu
    Prasad, Haarindraprasad Rajintra
    Maheswaran, Solayappan
    BIOSENSORS-BASEL, 2022, 12 (03):
  • [23] IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response
    Mingyue Yao
    Wenzhong Yan
    Yafang Wang
    Yu Zhao
    Xiaowei Xu
    Yujun Chen
    Chengcheng Yu
    Yingnian Li
    Hualiang Jiang
    Jie Shen
    Jianjun Cheng
    Chengying Xie
    Experimental Hematology & Oncology, 14 (1)
  • [24] Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress
    Doshi, Kshama A.
    Trotta, Rossana
    Natarajan, Karthika
    Rassool, Feyruz V.
    Tron, Adriana E.
    Huszar, Dennis
    Perrotti, Danilo
    Baer, Maria R.
    ONCOTARGET, 2016, 7 (30) : 48280 - 48295
  • [25] Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study
    Nelson, Ka Lam
    Lynn, Claire
    Leung, Thomas Wing Yan
    So, Eric Chi Wai
    Leung, Anskar Yu Hung
    BLOOD, 2019, 134
  • [26] Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3-ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors
    Levis, Mark J.
    Shi, Wenge
    Chang, Ken C. N.
    Laing, Christian
    Berisha, Flora
    Adams, Emily
    Gocke, Christopher D.
    Ding, Wei
    Nakamaru, Kenji
    Lameh, Jelveh
    Pollner, Reinhold
    Kobayashi, Ken
    BLOOD, 2018, 132
  • [27] Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.
    Martinelli, Giovanni
    Perl, Alexander E.
    Dombret, Herve
    Kayser, Sabine
    Steffen, Bjoern
    Rousselot, Philippe H.
    Estey, Elihu
    Burnett, Alan K.
    Shah, Neil P.
    Gammon, Guy
    Trone, Denise
    Levis, Mark J.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Development of a novel next-generation sequencing (NGS)-based assay for measurable residual disease (MRD) in FLT3-ITD acute myeloid leukemia (AML) and its potential clinical application in patients
    Shi, Wenge
    Laing, Christian
    Ding, Wei
    Mycoco, Marc
    Lameh, Jelveh
    Pollner, Reinhold
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Concurrent treatment with Pim kinase inhibitor decreases alternative non-homologous end-joining repair of DNA damage induced by topoisomerase 2 inhibitors in cells with FLT3-ITD
    Doshi, Kshama A.
    Nagaria, Pratik K.
    Tron, Adriana E.
    Rassool, Feyruz V.
    Baer, Maria R.
    CANCER RESEARCH, 2017, 77
  • [30] Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11
    Katsumoto, Takuo
    Kitabayashi, Issay
    BLOOD, 2011, 118 (21) : 1481 - 1481